An expert panel of India's drug regulator on Friday sought additional data from drugmaker Dr.Reddy's Laboratories on its Sputnik V COVID-19 vaccine trial, in its second such request after an initial evaluation in February.
The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study, as well as data on serious adverse events and positive cases reported till date.
Dr. Reddy's has been conducting small clinical trials with Sputnik V in India under a deal with Russia's wealth fund. Several Indian companies have signed deals to produce and supply over half a billion doses of the vaccine.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
New XEC Covid Variant Spreads To 27 Countries, Here's What We Know So Far Study Shows How Long Covid Is Debilitating Children's Health From FLiRT To FLuQE: What To Know About The Latest Covid Variants India A "Cyber Adversary", Says Trudeau Government, New Delhi Shreds Claim 'Will Return With...': Swati Maliwal Pours Dirty Water Outside Atishi's Home Woman Strips At Iran University To Protest Strict Dress Code: Reports The Impact Of The World's Richest Man On US Democracy GATE 2025: Application Correction Deadline Extended, Details Here Fire Breaks Out At Factory In Delhi's Alipur, 34 Fire Tenders Rushed Track Latest News Live on NDTV.com and get news updates from India and around the world.